Exchange: NYSE·Updated 05:43 PM EDT

BMY News

News
all
press releases
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) versus daratumumab, bortezomib, and...
Business Wire
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) versus daratumumab, bortezomib, and...
Business Wire
More News
Top Stock Reports for Tesla, Bank of America & Coca-Cola
Tesla, Bank of America and Coca-Cola headline today's research, with growth drivers, investment plans and key risks in focus.
Zacks
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Zacks
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
Zacks
New Strong Buy Stocks for September 24th
BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
Zacks
Best Income Stocks to Buy for September 24th
ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.
Zacks
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Zacks
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
Zacks
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Zacks

Advertisement|Remove ads.